Wall Street Analysts Raise Price Targets for West Pharmaceutical Stock

West Pharmaceutical Services, Inc. (WST), based in Exton, Pennsylvania, has caught the attention of investors and analysts following a significant uptick in its stock price after the company reported strong third-quarter results. On October 23, 2023, West Pharmaceutical announced that its net sales surged 7.7% year-over-year, reaching $804.6 million, surpassing analyst expectations by 2.4%. This positive momentum saw the stock price rise by 10.9% in a single trading session.

Despite these promising results, West Pharmaceutical has struggled to keep pace with the broader market over the past year. The company’s stock has decreased by 17.3% over the past 52 weeks and 21.3% year-to-date. In contrast, the S&P 500 Index has gained 10.5% during the same period, while the Healthcare Select Sector SPDR Fund has increased by 6%. Such discrepancies highlight a challenging environment for the company, which has a market capitalization of $18.6 billion and operates across multiple regions, including the Americas, Europe, and the Indo-Pacific.

Looking ahead, analysts remain optimistic about West Pharmaceutical’s performance. The consensus rating among the 15 analysts covering the stock is a “Strong Buy,” with a breakdown of 11 “Strong Buys,” one “Moderate Buy,” and three “Holds.” This reflects a slight increase in positive sentiment compared to last month, when only 10 analysts recommended “Strong Buy” ratings.

On October 29, 2023, Brendan Smith, an analyst at TD Cowen, initiated coverage of West Pharmaceutical with a “Buy” rating and established a price target of $350. This target represents a potential upside of 35.8% from current levels. Additionally, the highest target among analysts is set at $390, indicating a notable 51.3% upside potential.

For the fiscal year ending in December 2025, analysts project an adjusted earnings per share (EPS) of $7.07, reflecting a 4.7% increase year-over-year. West Pharmaceutical has demonstrated a solid track record in exceeding earnings expectations, having surpassed the Street’s bottom-line estimates in each of the past four quarters.

As West Pharmaceutical navigates a competitive market landscape, its recent financial performance and analysts’ bullish outlook may position the company for recovery and growth in the upcoming quarters.